U.S. License Holder:
Incyte Corp.
Date of License:
March-22-2023
Last Update:
Sep-30-2024
FDA-Approved Indications
ZYNYZ (retifanlimab-dlwr) is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.